Rozwój badań w kardioonkologii Mini-review: future in cardio-oncology
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lut 22, 2016
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Dent S, Aseyev O, Lenihan D. Rozwój badań w kardioonkologii. OncoReview [Internet]. 22 luty 2016 [cytowane 23 listopad 2024];6(1(21):27-8. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/474
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives. Oncology (Williston Park) 2015; 29(11): 843-844, 846.
2. Amiri-Kordestani L, Wedam S, Zhang L et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014; 20(21): 5359-5364.
3. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice. Fed Requist 2010; 75(44): 10487-10488.
4. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63(4): 249-279.
5. Herndon TM, Deisseroth A, Kaminskas E et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19(17): 4559-4563.
6. Sysa-Shah P, Tocchetti CG, Gupta M et al. Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc Res 2015; Dec 21. pii: cvv274 [epub ahead of print].
2. Amiri-Kordestani L, Wedam S, Zhang L et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014; 20(21): 5359-5364.
3. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice. Fed Requist 2010; 75(44): 10487-10488.
4. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63(4): 249-279.
5. Herndon TM, Deisseroth A, Kaminskas E et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19(17): 4559-4563.
6. Sysa-Shah P, Tocchetti CG, Gupta M et al. Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc Res 2015; Dec 21. pii: cvv274 [epub ahead of print].